Upgrade to SI Premium - Free Trial

Medicinova (MNOV)

1.32 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/14/26)

Latest Headlines

MediciNova reaches 200-patient enrollment in NIH-funded ALS study July 15, 2026 8:03 AM - StreetInsider MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients July 15, 2026 8:00 AM - StreetInsider MediciNova completes last patient visit in NAFLD Phase 2 trial June 30, 2026 8:01 AM - StreetInsider MediciNova CEO Provides Shareholder Update June 30, 2026 8:00 AM - StreetInsider Form 4 MEDICINOVA INC For: Jun 23 Filed by: Nagao Hideki June 25, 2026 4:38 PM - SEC Filing Form 4 MEDICINOVA INC For: Jun 23 Filed by: Lemerond Nicole June 25, 2026 4:35 PM - SEC Filing Form 4 MEDICINOVA INC For: Jun 23 Filed by: BEAVER CAROLYN June 25, 2026 4:35 PM - SEC Filing Form 8-K MEDICINOVA INC For: Jun 23 June 24, 2026 4:39 PM - SEC Filing MediciNova receives patent allowance for glioblastoma combination therapy June 8, 2026 8:00 AM - StreetInsider MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment June 8, 2026 8:00 AM - StreetInsider MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) May 26, 2026 7:00 PM - StreetInsider Form 10-Q MEDICINOVA INC For: Mar 31 May 14, 2026 4:16 PM - SEC Filing Form ARS MEDICINOVA INC For: Dec 31 April 29, 2026 4:35 PM - SEC Filing Form DEFA14A MEDICINOVA INC April 29, 2026 4:33 PM - SEC Filing Form DEF 14A MEDICINOVA INC For: Jun 23 April 29, 2026 4:27 PM - SEC Filing Full Article List